Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Photocure ASA (Photocure), an in vitro diagnostics company, has reported sales revenues of NOK29.1 million for the first quarter of 2009, up 36%, compared with the sales revenues of NOK21.4 million in the year-ago quarter. It has also reported a net loss of NOK8.6 million for the first quarter of 2009, compared with the net loss of NOK20 million in the year-ago quarter.
Subscribe to our email newsletter
The main items in the report are:
Highlights
Operating profit improved by NOK16.7 million to NOK-5.7 million (NOK-22.5 million)
Liquid funds amounted to NOK161.9 million at the end of the period.
Cevira – patient recruitment started in phase I/II study for photodynamic treatment of precancerous lesions of the cervix.
Lumacan – patient recruitment started in phase I/II study for photodynamic detection of colon cancer using an oral capsule as administration of the drug.
Photocure won a patent case extending the patent on Metvixia™ in the USA until July 2018.
President and chief executive officer of Photocure, Kjetil Hestdal MD, PhD, says in a comment to the results, “We are pleased to present another quarter with growth in sales of Hexvix and Metvix/Aktilite.
Photocure has now a positive contribution to the operating profit in the Nordic region, reflecting the previous investment in marketing and sales.”